Program
Minoxidil
Also written as “Minoxidil Tablets”, “minoxidil + finasteride” and “Minoxidil oral solution”.
Its studies are mostly in Alopecia · Hypotrichosis, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aneira Pharma | 21 open or running | phase 1since May 8, 2023 | Mar 17, 2023 | none ahead |
| Galderma Group | 20 open or running | no phasesince May 29, 2015 | May 29, 2015 | none ahead |
| Industrial Farmacéutica Cantabria | 21 open or running | phase 3since May 25, 2023 | May 25, 2023 | none ahead |
| Johnson & Johnson | 20 open or running | phase 3since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| 3SBio | 11 open or running | phase 3since Jul 15, 2025 | Jul 15, 2025 | Dec 2027phase 3 · NCT07080931 |
| Beijing Dayspring Pharmaceutical Technology | 10 open or running | phase 2since Jul 1, 2025 | Jul 1, 2025 | none ahead |
| Eurofarma Laboratorios | 11 open or running | phase 3since Apr 8, 2026 | Apr 8, 2026 | Oct 30, 2028phase 3 · NCT07529977 |
| Maja Kovacevic, MD | 10 open or running | no phasesince Jun 25, 2015 | Jun 25, 2015 | none ahead |
| Samson Clinical Operations Pty | 10 open or running | phase 3since Apr 6, 2025 | Apr 6, 2025 | none ahead |
Also a collaborator on its studies: bioskin-gmbh and astrum-cro-s-l.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2005First study: phase 3 study in AlopeciaNew to Johnson & JohnsonJohnson & Johnson · NCT00151515 · 352 enrolled · United States
- Jun 15, 2010Phase 3 study in AlopeciaJohnson & Johnson · NCT01145625 · 322 enrolled · United States, Canada, France and more
- May 29, 2015Galderma Group's first studies: 2 no phase studies in AlopeciaNew to Galderma GroupGalderma Group · NCT02460497, NCT02460289
- Jun 25, 2015Maja Kovacevic, MD's first study: no phase study in AlopeciaNew to Maja Kovacevic, MDMaja Kovacevic, MD · NCT02486848 · Italy
- Mar 17, 2023Aneira Pharma's first study: early phase 1 study in HypotrichosisNew to Aneira PharmaAneira Pharma · NCT05790941 · 12 enrolled · United States
- May 8, 2023Phase 1 study in AlopeciaAneira Pharma · NCT05864885 · 14 planned
- May 25, 2023Industrial Farmacéutica Cantabria's first study: phase 3 study in AlopeciaNew to Industrial Farmacéutica CantabriaIndustrial Farmacéutica Cantabria · NCT05888922 · 520 enrolled · Germany, Italy, Portugal and more
- May 31, 2023Phase 1 study in HealthyIndustrial Farmacéutica Cantabria · NCT06015516 · 14 enrolled · Spain
- Apr 6, 2025Samson Clinical Operations Pty's first study: phase 3 study in AlopeciaNew to Samson Clinical Operations PtySamson Clinical Operations Pty · NCT06924632 · 142 enrolled · Australia
- Jul 1, 2025Beijing Dayspring Pharmaceutical Technology's first study: phase 2 study in AlopeciaNew to Beijing Dayspring Pharmaceutical TechnologyBeijing Dayspring Pharmaceutical Technology · NCT07076706 · 110 enrolled · China
- Jul 15, 20253SBio's first study: phase 3 study in AlopeciaNew to 3SBio3SBio · NCT07080931 · 294 planned · China
- Apr 8, 2026Eurofarma Laboratorios's first study: phase 3 study in AlopeciaNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT07529977 · 372 planned · Brazil
Ahead
- Dec 2027Primary completion: phase 3 study in Alopecia3SBio · NCT07080931
- Oct 30, 2028Primary completion: phase 3 study in AlopeciaEurofarma Laboratorios · NCT07529977
TargetBeta
“Sulfonylurea receptor 2, Kir6.2 opener”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07529977Alopecia · Brazil | 3 | Not yet recruiting | Eurofarma Laboratorios | Oct 30, 2028 | 372 |
| NCT07080931Alopecia · China | 3 | Recruiting | 3SBio | Dec 2027 | 294 |
| NCT07076706Alopecia · China | 2 | Completed | Beijing Dayspring Pharmaceutical Technology | Aug 26, 2025 | 110 |
| NCT06924632Alopecia · Australia | 3 | Completed | Samson Clinical Operations Pty | May 15, 2026 | 142 |
| NCT06015516Healthy · Spain | 1 | Completed | Industrial Farmacéutica Cantabria | Mar 8, 2024 | 14 |
| NCT05888922Alopecia · Germany, Italy, Portugal and more | 3 | Active, not recruiting | Industrial Farmacéutica Cantabria | Oct 2026 | 520 |
| NCT05864885Alopecia | 1 | Not yet recruiting | Aneira Pharma | Jul 17, 2023 | 14 |
| NCT05790941Hypotrichosis · United States | Early 1 | UNKNOWN | Aneira Pharma | Jun 30, 2023 | 12 |
| NCT02486848Alopecia · Italy | – | Withdrawn | Maja Kovacevic, MD | Dec 2016 | 0 |
| NCT02460497Alopecia · United States | – | Completed | Galderma Group | Sep 19, 2015 | 61 |
| NCT02460289Alopecia · United States | – | Completed | Galderma Group | Nov 2015 | 63 |
| NCT01145625Alopecia · United States, Canada, France and more | 3 | Completed | Johnson & Johnson | Feb 2012 | 322 |
| NCT00151515Alopecia · United States | 3 | Completed | Johnson & Johnson | Jul 2004 | 352 |
How it is read
Names in the registry
- “Minoxidil Tablets”, 2 entries
- “Minoxidil”, 2 entries
- “minoxidil + finasteride”, 2 entries
- “Minoxidil oral solution”, 1 entry
- “5% minoxidil foam”, 1 entry
Conditions, from the studies’ own filings
- Alopecia, 11 studies
- Hypotrichosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.